Jump to Main Content

ASH Annual Meeting Abstracts

2024 Call for Abstracts 

INFORMATION FOR AUTHORS

The 66th ASH Annual Meeting and Exposition will be held Saturday, December 7, through Tuesday, December 10, 2024, in San Diego, California. The meeting will be in person, with a virtual attendance option, however, presenting authors of abstracts chosen for oral or poster presentation must be on-site in San Diego. The goal of the ASH annual meeting is to present the best new and significant basic, translational, clinical, and epidemiological research in all areas of hematology. The meeting content will also be accessible to virtual meeting attendees via the virtual meeting platform.

To aid in submission, our Author Reference Guide for Annual Meeting Abstracts is available to download.

Eligibility

To submit an abstract, the following criteria must be met:

  • At least one of the authors must be a current ASH member with up-to-date payment of membership dues.
  • If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.
  • The content of the abstract must fit into one of the ASH 2024 categories.
  • In contrast to past years, oral abstract and poster presentations will no longer be contained within the ACCME-accredited portion of the annual meeting. Therefore, presenting authors are no longer subject to ACCME restrictions, and can be employees of publicly-traded or privately-held healthcare companies or owners of privately-held entities. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently.
  • Abstracts describing work posted to a preprint server prior to submission to ASH will be considered, but preprint posting must be disclosed and a link to the preprint provided. Preprints are not accepted for late-breaking submissions.
  • Authors must retain copyright of the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per ASH’s copyright policy.
  • Once the abstract is submitted to ASH, no further changes can be made to the preprint, including the abstract, nor may the preprint be updated if the abstract is accepted for presentation at ASH.
  • Upon abstract acceptance for presentation at the annual meeting, the contents and conclusions of the abstract are embargoed from publication and must adhere to ASH's annual meeting embargo policy.

Any of the following criteria will make an abstract ineligible for acceptance at the ASH annual meeting:

  • Data from peer-reviewed content is publicly available via major search engines (such as PubMed, Google Scholar, etc).
  • Data are accepted for journal publication before the ASH abstract submission closing date, August 1, 2024. Any abstract submission accepted for publication before August 1, 2024 must be withdrawn. Authors must notify ASH if, after the August 1st submission deadline, the work submitted is accepted for journal publication and will be published online or in print before the ASH Annual Meeting. In this instance, authors must request a delay in publication and refrain from posting on a preprint publication portal for accepted papers. ASH will strive to coordinate the publication with your presentation as well as any potential press releases.
  • Identical or virtually identical data have been or are to be presented at a meeting of 3,000 or more participants before the 2024 ASH Annual Meeting. Updated analyses of work previously presented at ASH or other meetings of more than 3,000 participants will be considered only if the abstract is a significant extension of previously presented work. The author must provide an explanation documenting the significant new information. Failure to disclose prior presentation may result in rejection of the abstract.
  • Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 6, 2024.
  • Once an abstract is accepted, the presenting author is the sole contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
  • The presenting author must be one of the co-authors listed on the submitted abstract.
  • The presenting author is responsible for the following:

    • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
    • Ensuring all co-authors provide conflict-of-interest disclosures and copyright transfer information.
    • Forwarding all correspondence from ASH to all co-authors, including ASH policies and guidelines relating to disclosure of financial relationships.
  • Presenting authors of abstracts accepted for oral or poster presentation must attend the 2024 Annual Meeting in person in San Diego. The presenter can be changed on the Author(s) tab of the submission process up until August 1, 2024, 11:59 p.m. Pacific time. After this deadline, if a presenting author is unable to attend or needs to be replaced by a co-author who can attend the meeting in person, please notify [email protected] immediately.
  • If the abstract is accepted for oral or poster presentation, given the Society’s commitment to the importance of clinical trial enrollment reflecting the spectrum of the general population at risk for the disease under investigation, ASH requests that demographic information regarding, sex, gender, race, ethnicity, age, disability, or other relevant factors of enrolled subjects be included in an oral or poster presentation, if this information is available. If some or all information is not available, we ask that presenters disclose in their oral or poster presentation the limitations that led to such data not being collected.

Each abstract author agrees and certifies that they:

  • Have read all the rules and agrees to be bound by them;
  • Are responsible for submission of the abstract in accordance with the rules;
  • Waive any and all claims against ASH and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Policies

  • Text generated by AI may not be included in the abstract.
  • ML/AI tools are not eligible for authorship and may not be listed as an author.
  • Research that used ML/AI tools for data acquisition or analysis is eligible for submission.
  • Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
  • Learn more about the Annual Meeting's copyright and reuse policy for abstracts, presentations, and presentation materials.
  • Other than abstracts, materials presented at the ASH Annual Meeting or requested for submission by ASH in conjunction with the Annual Meeting, including but not limited to posters, on-screen presentations (e.g., PowerPoint slides, pre-recorded presentations) and hand-outs are the intellectual property of individual presenters or entities other than ASH. Although ASH is not the copyright holder of such other presentation materials, presenters grant an exclusive license to ASH to use such other materials in connection with the presentation (see below).
  • By presenting at the ASH Annual Meeting, the presenter grants to ASH: (a) the exclusive right to broadcast, record, create plain language summaries, and otherwise use my presentation in whole or in part, including all documents, slides or other materials displayed or distributed in connection with my presentation (collectively, the "Work"), in any media whatsoever; and (b) a perpetual, irrevocable, worldwide, royalty-free, exclusive license to re-present, reproduce, redistribute and otherwise use (and to license others to use) the Work in any and all media throughout the world. Presenters further grant to ASH the right to use (and to license others to use) the presenter's name, image, likeness, voice, and biographical information in connection with the Work.
  • Abstracts submitted to ASH are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting has concluded. (Note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.) Read the Annual Meeting Embargo Policy webpage for more details.

Trials in Progress

Abstracts of Trials in Progress (TiPs), i.e., descriptions of trials that have not reached the primary endpoint and cannot include any clinical data, are eligible for submission to the ASH Annual Meeting. TiP abstracts are expected to provide investigators with opportunities to discuss planned and ongoing clinical trials with other clinical and industry investigators, hematologists interested in referring patients, translational researchers, statisticians, and regulators. The TiP poster platform will help increase the visibility of ongoing clinical trials, and ultimately facilitate patient recruitment.

Trials in Progress submissions will only be considered for poster presentations and will be designated as TiPs in the poster hall. TiPs will be selected for poster presentation by dedicated review panels only considering the pool of submitted TiP abstracts. Any abstract submitted as a TiP that contains clinical endpoint or other clinical data will be immediately withdrawn from consideration. Thus, abstract authors should submit abstracts containing any interim clinical trial results as regular abstracts, NOT as TiPs.



In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria:

  • The trial described must fit into one of the ASH 2024 Abstract Review Categories.
  • The clinical trial registration number (with ClinicalTrials.gov or another accepted clinical trials registry) must be provided in the abstract.
  • Clinical studies submitted as TiP abstracts must be in the study design phase, or if active or ongoing, should NOT have reached the clinical endpoints for analysis. All phases of clinical research interventional studies (phases I to III, supportive care, nonpharmacologic interventions) may be considered as a TiP submission.
  • Abstracts containing ANY clinical endpoint or other clinical data, and submitted as a TiP, will be deemed ineligible and completely withdrawn from consideration for presentation at the ASH Annual Meeting.
  • Background and Significance: TiP abstracts should contain the scientific rationale for the trial to be presented, for instance, information on preclinical studies as well as previously published clinical data that informed and helped guide the development of the current study.
  • Study Design and Methods: The study design should highlight any innovative features of trial design, analytic methodologies, or study drugs and/or treatment modalities. It must include:

    • A clinical trial registration number as detailed above;
    • A description of the study population;
    • General location of participating centers (single center, or if multicenter, whether a single country, region or worldwide);
    • Major inclusion and exclusion criteria,
    • Statistical methods;
    • Biomarker selection or companion diagnostics (if appropriate); and
    • Study treatment and relevant primary and other endpoints.

The abstract must not contain any clinical endpoint data but may contain information on regulatory issues, experience with recruitment, current recruitment status, patient characteristics, and/or changes in inclusion and/or exclusion criteria or study design. Abstracts containing endpoint data and submitted as a TiP will be deemed ineligible and withdrawn from consideration.

Abstract Submission Guidelines

  • No revisions in abstract content can be made after the abstract submission deadline (August 1) This includes changes to the spelling of authors’ names and the order of co-authors.
  • Please proofread the abstract to ensure that it does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted.
  • Abstracts should be written in clear and concise English so that reviewers are able to focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling before submission.
  • During online submission, the author must indicate whether they want to have their abstract withdrawn if it accepted as “publication-only.” Abstracts may not be withdrawn after September 18, 2024. In other words, authors may not request to have their abstract withdrawn because it was not selected for oral or poster presentation. Unless the author opts for automatic withdrawal at the submission stage should the abstract be selected for publication-only, the abstract will be published.
  • There is a $85 nonrefundable handling fee for submitting an abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register for the meeting.
  • During submission, ASH staff are authorized to communicate only with the presenting or corresponding author. Notifications of whether an abstract has been accepted will be sent to the presenting author by early October 2024. After acceptance, ASH staff will only communicate with the presenting author regarding any abstract-related matters, including requests for withdrawal, which must be submitted in writing. Any queries or requests from co-authors or non-authors, including pharmaceutical companies or medical communications companies, must go through the presenting author. Any attempts to contact ASH directly by such individuals will not be responded to.


  • ASH is committed to ensuring the integrity of its scientific, educational, and research programs. The ASH Conflict-of-Interest Policy requires disclosure of any financial or other interest in the biomedical industry that might be construed as resulting in an actual, potential, or apparent conflict, regardless of the relationship’s pertinence to the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH.
  • As a continuing medical education (CME) provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), ASH must ensure balance, independence, objectivity, and scientific rigor in all presentations at the ASH annual meeting.
  • ASH abides by rules formulated by the ACCME that require that authors disclose any financial relationship they or their spouse/partner have had within the past 24 months with an ineligible company (formerly commercial interest) as defined by the ACCME.
    • Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients. Examples of such companies can be found on the ACCME website.
  • For this purpose, “financial relationships” are those in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committee or review panels, board memberships, and other activities from which remuneration is received, or expected. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.
  • By completing this section of the online abstract submission, the author agrees that they have read the ASH Conflict-of-Interest Policy and that they understand and support its intent.
  • This policy is not intended to prevent a presentation; it is merely intended to openly identify potential conflicts so that audience members may form their own judgments about the presentation with a full disclosure of the facts.
  • Appropriate disclosure will be stated in the special online-only abstract issue of Blood. Abstracts will not be considered for the program without completion of disclosure information for all the authors.
  • The presenting author is responsible for obtaining financial disclosure information from all co-authors.
  • All authors and co-authors are required to provide any information concerning personal or professional circumstances and financial relationships with ineligible companies that might reasonably be expected to affect the author’s view on the presentation.
  • This includes funding or other support provided by commercial entities to carry out the research being presented, or other relationships with pharmaceutical companies, biomedical device manufacturers, biomedical startups that have begun a governmental regulatory approval process, or other companies whose products or services are related to the subject matter of the presentation topic. If no financial relationships with ineligible companies exist, this must be stated as well.
  • Please disclose any relationships with ineligible companies regardless of the relationship’s pertinence to the content of the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH. Disclosure includes relationships held by the author or any individual with whom they directly share income, such as a spouse or partner.

Authors must disclose the relationship type and the name of the ineligible company for each of the following areas in which they maintain a relationship. Exact dollar amounts are not necessary. Authors will have the option to (a) note that there are no financial relationships to disclose or to (b) provide relationship information. Disclosed information may include the following areas:

  • Employment (current or ended)
  • Consultancy
  • Equity holder in publicly traded company
  • Equity holder in privately-held company (including stock options, but excluding indirect investments through mutual funds and the like) in a publicly traded company
  • Research or clinical trial funding or other support (including grants received by the author’s institution)
  • Honoraria directly received from an entity
  • Patents and royalties
  • Paid expert testimony
  • Membership on an entity’s board of directors, speaker’s bureau, or its advisory committees
  • Any other financial relationship with an ineligible company
  • Authors will be required to note whether their presentation will include discussion of off-label use of products. If so, authors should use the Off-Label Disclosure section of the abstract form to identify the product(s) and off-label use(s).

During the disclosure submission process, authors will also be required to indicate their compliance with the following statements, which include measures to ensure clinical content validity:

  • The content I am responsible for will only use generic names of products, or if trade names appear, is the use of those trade names will be justified (e.g., product is known more widely for the trade name, or the product does not have a generic name).
  • The content I am responsible for will be free of logos or other corporate identifiers of healthcare industry companies, specifically those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
  • Any recommendations for patient care must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options.
  • All scientific research referred to, reported, or used to support or justify a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation.
  • I am unaware of any allegations of research improprieties concerning any research that will be referenced in the content for which I am responsible in connection with my presentation.
  • If I discuss off-label, unlabeled, experimental, and/or investigational product use, I will disclosure to participants/readers that the use is not approved in the United States for the use under discussion.
  • If I discuss new and evolving topics for which there is a lower (or absent) evidence base I will clearly identify it as such within the individual presentations.
  • The presentation of the information with which I am involved will avoid advocating for, or promoting, practices that are not or not yet adequately based on current science, evidence, and clinical reasoning.
  • The presentation of the information with which I am involved will exclude any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.The presentation of the information with which I am involved will exclude any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
  • I will remove all patient identifiers (name, birth date, address, phone number, medical record number, account number, social security number, etc.) from my presentation materials. I will not use identifiable photographs of patients unless I have obtained written permission from the patient.
  • If I have been trained or utilized by an ineligible company (commercial interest) or its agent as a speaker (e.g., speakers’ bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity or publication.
  • I agree not to accept honoraria or reimbursement, including travel support, from ineligible companies for my role as a chair/moderator/presenter in the accredited portions of this activity.
  • I agree not to actively promote or sell products or services that serve my professional or financial interests during accredited education.
  • Abstracts submitted to the ASH annual meeting are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting has concluded. (Note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.)
  • For the research to be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented about the research at the annual meeting, may not be made public before the abstract has been published/presented at the ASH annual meeting.
  • Prior to the embargo being lifted, the first author, co-authors, and sponsor of the abstract must not:
    • Publish the information or provide it to others who may make it publicly available.
    • Release the research/study to news media, or
    • Use the information for trading in the securities of any issuer or provide it to others who may use it for securities-trading purposes.
  • An exception may be granted in cases in which the Securities and Exchange Commission (SEC) requires a press release to comply with security laws. ASH will consider such requests on an ad hoc basis. More information on requesting such an exception can be found on the ASH website.
  • Authors must notify ASH if, after the submission deadline (August 1, 2024), the work submitted for publication is accepted for journal publication and will be published online or in print before the ASH annual meeting. In this instance, authors should request a delay in publication and refrain from posting on a preprint publication portal for accepted papers. ASH will strive to coordinate the publication with the presentation as well as any potential press releases.
  • If the Embargo Policy is violated, the abstract may be withdrawn by ASH from presentation at the annual meeting and from publication.
  • More detailed information about the Society’s Embargo Policy is located on the ASH website. Please contact ASH Communications Manager Melissa McGue at [email protected] or 202-552-4927 with any questions.

How to Submit an Abstract


All abstracts must be submitted by August 1, 2024, at 11:59 p.m., Pacific time. All Submissions that are incomplete by the deadline will be rejected.

  • Abstracts must be submitted online through the official online abstract submission system. Abstracts sent via e-mail to ASH will not be accepted.
  • There is a $85 non-refundable handling fee for submission of each abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register.
  • Electronic submission works optimally with Microsoft Internet Explorer 7+, Mozilla Firefox 3.0+, and Safari or MAC OS 10.4+. Netscape Navigator 7.7+ is supported, but its use is discouraged since not all features are available. The online abstract submission system will provide links for free browser downloads.
  • If this is the first time that you are submitting an abstract for the ASH annual meeting, please be sure to check the box indicating so during submission.
  • Once authors have submitted the title of the abstract, a draft will be saved, and the submitting author will be able to return to the site to edit and update the submission at any time until August 1, 2024, at 11:59 p.m., Pacific time. The submitting author will receive an e-mail providing a link to their submission.
  • Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the “Submission Information” and “Disclosure” sections of the online abstract submission program.
  • Any technical questions regarding navigation of the submission site itself should be directed to [email protected]. It is advisable not to leave submission of the abstract to the final day or hours, giving time for ASH staff and Confex to assist with any technical problems during the submission process.

Submit an Abstract

Submitting an Abstract

  • Please refer to the list of this year’s abstract review categories, which provides detailed descriptions of each category, to assist in selecting the correct abstract classification.
  • Note that categories are frequently redefined and renumbered; please read through each category before making a selection. Failure to carefully review categories may result in misplacement and therefore rejection or low scoring of the work.
  • An abstract must include primary new scientific, clinical, meta-analytic, health outcomes, or epidemiologic data. The only exceptions are Trials in Progress abstracts.
  • ASH expects all scientific research submitted or presented as part of the abstract program to conform to the generally accepted standards of scientific integrity regarding experimental design, data collection, analysis, and interpretation.
  • All studies reported in submitted abstracts involving human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
  • Data from long-term follow-up or additional accrual to previously-presented or published clinical trials may be submitted only if the abstract includes significant new information. In this case, authors must use the Updated Analyses section of the abstract form to explain the extent and the significance of the new data. The reviewers will have this information available during their evaluation.
  • Interim analysis of a prospective randomized clinical trial will be considered for presentation only if such an analysis is performed as planned in the original protocol or results from the trial being closed early due to unexpected toxicity, futility, or benefit If the abstract involves interim analysis, authors must use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of the study. The reviewers will have this information available during their evaluation.
  • The corresponding author must provide their name, degree, institutional affiliation, address, phone number, and e-mail address. All correspondence from ASH will be sent to the corresponding author during the submission period. If an abstract is accepted, all subsequent correspondence will be sent to the presenting author.
  • If none of the abstract authors is an ASH member, the program will ask the submitting author to provide the name of the ASH member who is sponsoring the abstract.
  • Names of all co-authors and their institutional affiliations must be provided. Please proofread the co-authors’ names carefully. The program will automatically place an asterisk (*) after the name of each non-member author. Changes will not be made to the spelling of authors’ names, or the order of co-authors, after the submission deadline.
  • Shared authorship (i.e., more than one first author) is not permitted.
  • The abstract title should be brief and clearly indicate the nature of the abstract.
  • The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive.
  • Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
  • Do not put a period at the end of the title.
  • For example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies
  • Abstracts submitted for the ASH annual meeting are published in a special online-only November 2024 issue of Blood, a Journal of the American Society of Hematology. Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract and author list carefully.
  • The entire body of the abstract must not exceed 3,800 characters. Spaces are not included in this number. The title, authors’ names, and authors’ affiliations are not included in the character count.
  • The body of the abstract is to be pasted into the submission form.
  • Figures and tables are not permitted. However, if the abstract is selected for oral or poster presentation, authors may include figures and tables in the presentation materials.
  • The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
  • Do not use bold type or underline formatting. Italic type is acceptable.
  • Text may be in multiple paragraphs.
  • Special Greek and mathematical symbols are available in a character map within the submission system. Pay careful attention to superscripts, type case font sizes, and special characters when copying/pasting abstract text.
  • Use numerals to indicate numbers, except when beginning sentences.
  • Any references should be noted as citations within the text and not as footnotes at the end of the abstract.
  • Non-proprietary (generic/scientific) names should be used and should be lowercase.
  • If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.
  • Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Presentation

  • The presentation at the annual meeting must reflect the content of the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates of data included in the abstract may be included.
  • Abstracts cannot be changed after the submission deadline (August 1) and may not be withdrawn after September 18, 2024.
  • During submission, the authors may elect to have their abstract considered for a “poster-only” presentation. By making this selection, the abstract will not be considered for oral presentation, regardless of the score. Choose this option if the presenting author is unwilling or unable to give an oral presentation in English. This choice must be made during the submission process and cannot be changed after the Review Committee has reached its decision.
  • Depending on the number of submissions and the space constraints at the venue, ASH may not be able to accommodate all qualified submissions for an oral or poster presentation. In such a case, the submission may be accepted and designated as “publication-only.” Publication-only submissions will be published in the online-only issue of Blood (which is part of the permanent Blood archive) but will NOT be scheduled for presentation at the annual meeting, nor featured in the web program, the meeting app, or the virtual meeting platform. During submission the author must indicate if they want to have the abstract withdrawn if it is accepted as “publication-only”. If the “publication-only option is selected, the presenting author will be notified by early October as to whether their abstract has been withdrawn due to being selected for publication-only.
  • After the submission deadline, all completed and eligible abstracts will be made available to the ASH Abstract Reviewers for double-anonymized review and scoring, and final decisions will be made by the Program Committee in late September 2024.
  • Abstracts will be evaluated and scored solely on their scientific merits. Trial in Progress abstracts will be flagged and reviewed by dedicated TiPs review panels based on the novelty of the methodology, quality of the study design, and interest to the hematology community.
  • The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
  • Abstracts will be peer-reviewed according to the subject categories. Authors must indicate the appropriate review category (one only) during online submission. Please use the list of abstract review categories when selecting the abstract classification. Please read through all the categories and select the category most closely associated with the abstract. Authors will not be able to reclassify their abstracts after the abstract submission site closes. The ASH Secretary may move abstracts between categories as deemed appropriate, however, abstracts submitted to an inappropriate category may be scored in that category and are often ranked poorly. Note that major changes in abstract category content and abstract category numbering have been made this year. Please read ALL category descriptions in detail before choosing a submission category.
  • The Plenary Session features six of the highest-scored abstracts submitted to the Annual Meeting, chosen by the Program Committee for their quality, significance, and general interest. These abstracts are introduced in the Plenary Session by an ASH member selected to place the abstract in context for a general hematology audience, followed by the author’s presentation and a brief discussion.
  • Oral (simultaneous) Sessions consist of 10-minute oral abstract presentations followed by a 5-minute discussion.
  • Poster Sessions allow in-person viewing of a poster illustration of the abstract. Poster presenters are required to record a narrated, 3-to-5 minute PowerPoint presentation as well as provide a graphic image of their poster for both in-person and virtual attendees. In-person presenters are expected to be at their posters to answer questions during their assigned poster presentation time. Posters and pre-recorded presentations are due to the submission system by November 12, 2024. Posters that are not uploaded by November 12 will be marked “unavailable” on the virtual platform and will NOT be printed or hung by ASH. Therefore, it will be the presenting author's responsibility to print and bring the poster to the meeting themselves. Presentations (narrated slide decks) that are not uploaded by November 12 will be marked "unavailable" on the virtual meeting platform.
  • Notification regarding acceptance or rejection of abstracts will be sent via e-mail to the presenting authors in early-October; consequently, providing an accurate e-mail address at submission is critical. If the abstract is accepted, the e-mail will specify whether it is accepted as plenary, oral, or poster presentation or whether it will be published online only, without a presentation. If the presenting author has not received an e-mail by October 1, 2024, contact [email protected].
  • To ensure that you can receive e-mail correspondence from ASH, please make sure that your e-mail software can receive mail from the confex.com and hematology.org domains. You should add [email protected] and [email protected] to your Safe Senders list and/or address book. If after completing your submission you don't receive a confirmation e-mail from the abstract system, you must contact your system administrator and make sure that both the confex.com and hematology.org domains are added to your permitted e-mail address list.
  • The decision of the ASH Program Committee regarding the acceptance and presentation of abstracts is final.
  • Once an abstract is accepted, a written request to withdraw must be submitted no later than September 18, 2024, to [email protected] by the designated presenting or corresponding author to withdraw the abstract for any reason. Abstracts will not be withdrawn after this deadline. No person other than the presenting author may contact ASH to request a withdrawal. The submitting author must ensure that all authors are aware of this policy and agree to honor it.
  • ASH reserves the right to withdraw abstracts that are in violation of the Society’s policies and guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
  • If indicated at submission that the authors wish to withdraw their abstract if it is not accepted for presentation, the abstract will be automatically withdrawn, and the presenting author will be notified; withdrawal does not need to be requested.
  • If after the September 18 withdrawal deadline, the presenting author of a poster is unable to attend the meeting in person and a co-author cannot be identified to replace the presenter, the author should submit a request to [email protected] to cancel the presentation. A poster cancellation means that a “canceled” sign will be hung on the assigned poster board on the presentation date. The abstract will remain published in the virtual program, mobile app, and Blood supplement.
  • All abstracts accepted for presentation (plenary, oral, or poster) at the ASH annual meeting are published in a special online-only issue of Blood, ASH's official journal, on the Blood website.
  • Abstracts not selected for presentation will also be published online-only on the Blood website. If an author does not want an abstract published if not accepted for presentation, the author must indicate that during submission. Publication permission cannot be withdrawn after abstract notification.
  • ASH reserves the right not to publish abstracts that do not fit into any of the review categories, abstracts that inappropriately promote commercial interests in the biomedical industry, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the Program Committee.

Recognizing that the results of timely top-quality research may not always be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts.

  • The late-breaking abstracts submission site will open October 16 and will close October 28, 2024.
  • During submission, authors of late-breaking abstracts will need to explain why their abstract was not ready by the regular deadline (August 1) and why it deserves to be considered as late-breaking. This information will be available to reviewers.
  • Only six abstracts will be accepted and presented in the Late-Breaking abstracts session on Tuesday, December 10, 2024, from 7:30 – 9:00 a.m. Pacific time. Authors should realize that selection for presentation is extremely competitive, with the quality and general significance of the presented Late-Breaking abstracts equivalent to Plenary Session or very top oral session abstracts. Case reports and interim trial results are NOT appropriate for late-breaking abstract submission.
  • There is a $125 nonrefundable handling fee for submitting a late-breaking abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted.
  • Late-breaking abstracts will undergo regular peer-review evaluation.
  • The accepted abstracts will be published online-only on the Blood website. Late-breaking abstracts not accepted for presentation will not be published in any form.

Abstract Achievement Awards

These $500 merit-based awards (formerly Travel Awards) are provided to trainees with high-scoring annual meeting abstracts of which they are the first or senior author and presenter in order to defray travel expenses to the annual meeting. Trainees who are both first-or-last author and presenter of the abstract are eligible for the ASH Abstract Achievement award. Recipients will be notified by email if they will receive an award by late October. The list of award recipients will also be posted on the ASH website by November.

Winners must register for and attend the meeting in-person and present their abstract in person in order to receive their award.


These $2,000 awards are provided to trainees with the highest scoring abstract (in each trainee category) of which they are the first-or-last author or presenter. Awardees also receive annual meeting travel reimbursement* (coach airfare and two nights’ hotel accommodation) in addition to the award.

Travel reimbursement is contingent on presenting in person at the annual meeting and is not applicable for virtual presentations.

The following individual awards are also part of the ASH Abstract Achievement Award Program: Details for each can be found here.

  • Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
  • ASH-Frank Toohey Abstract Achievement Award for Myelodysplastic Syndromes
  • Minority Graduate Student Abstract Achievement Award (MGASAAA)
  • ASH-IPIG Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • National Partner Society Abstract Achievement Awards

To be considered, individuals must meet specific eligibility criteria for the desired award and fall within (and select their trainee level form) one of the following trainee categories: undergraduate student, medical student, graduate student, resident physician, or postdoctoral fellow (MD or PhD).

Applicants must check the appropriate box in the area marked “Abstract Achievement/Outstanding Abstract Achievement Award Applicants” during the online abstract submission process. Applicants must also include with their abstract submission a letter from their senior investigator or program director typed on their institution’s letterhead confirming their trainee status. This letter should be signed by the senior investigator or program director, saved in PDF format, and uploaded to the online abstract submission system.

For the individual awards that are also part of the Abstract Achievement Award program, please visit http://www.hematology.org/awards/achievement-awards to view additional eligibility requirements and application instructions.

Electronic Signature

Completion of all required disclosure information in the online abstract submission system serves as an agreement and is accepted in lieu of a faxed signature. It certifies the ASH abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

  1. All authors approve of submitting this work for presentation and publication.
  2. The author(s) transfer(s) all copyright ownership of the named abstract to the American Society of Hematology (except when one or more authors are U.S. Government employees); OR the submitter has gained permission from the copyright holder of the previously published abstract for the abstract to be displayed in the ASH meeting mobile app and online program.
  3. All authors have read the ASH Conflict-of-Interest Policy and have acted in accordance with that policy.
  4. The author(s) agree(s) to materially confine the presentation to information in the abstract if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session.
  5. The presenting author or other designated will be available to present the abstract in person if selected for the program. The author(s) will immediately notify ASH if the presenting author must be changed.
  6. The data in the abstract have not been accepted for publication before the abstract submission closing date; nor will they be materially presented at a meeting of 3,000 or more participants before the ASH annual meeting (note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.); and are not to be presented at an ASH Friday Satellite Symposium. If the data have been made available on a preprint server, all ASH policies summarized above regarding preprints have been and will be followed.
  7. The author(s) are aware that the withdrawal deadline for ASH Annual Meeting abstracts is September 18, 2024, and understand that abstracts cannot be withdrawn after this date.

Sample Abstract

A sample abstract is provided for reference below. Note that the title, authors, and institutions are entered in separate fields in the submission form, not in the abstract body, as they are not included in the character count.

The LRF/ZBTB7A Transcription Factor Is a BCL11A-Independent Repressor of Fetal Hemoglobin Takeshi Masuda, PhD1, Xin Wang, PhD2, Manami Maeda, M.D., PhD1, Matthew C. Canver, B.S.3, Falak Sher, PhD3, Alister P.W. Funnell, PhD4, Chris Fisher, PhD5, Maria Suciu5, Gabriella E. Martyn4, Laura J. Norton4, Ruijia Zhu1, Ryo Kurita, PhD6, Yukio Nakamura, MD, PhD6, Jian Xu, PhD7, Douglas R. Higgs, FRS5, Merlin Crossley, DPhil4, Daniel E. Bauer, MD, PhD3, Stuart H. Orkin, M.D.8, Peter V. Kharchenko, PhD2 and Takahiro Maeda, MD, PhD1

1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 2Department of Biomedical Informatics, Harvard Medical School, Boston, MA 3Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 4School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia 5MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom 6Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Japan 7Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 8Department of Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Induction of fetal-type hemoglobin (HbF: α2γ2) is a promising means to treat hemoglobinopathies; however, precisely how HbF expression is silenced in adult erythroid cells is not fully understood. Such knowledge is essential to develop mechanism-based, targeted approaches to reactivate HbF production. Here, we show that Leukemia/lymphoma Related Factor (LRF), encoded by the ZBTB7A gene, is a novel and potent repressor of HbF production.

To assess the effects of LRF loss on the mouse erythroid transcriptome, we performed RNA-Seq analysis using splenic erythroblasts from control and LRF conditional knockout (Zbtb7aF/F Mx1-Cre+) mice. LRF-deficient adult erythroblasts showed significant induction of Hbb-bh1, but not Hbb-y. The results were validated at the protein levels via isoelectric focusing of peripheral blood (PB) hemolysates and MALDI-TOFMS analysis. LRF loss also reactivated human fetal globin expression in vivo in LRF conditional KO mice harboring the human β-globin gene cluster as a yeast artificial chromosome transgene (β-YAC).

To determine whether LRF loss could induce HbF in human erythroid cells, we employed human CD34+ hematopoietic stem and progenitor (HSPC)-derived primary erythroblasts and determined γ-globin expression levels upon shRNA-mediated LRF knockdown (KD). HbF levels in LRF KD cells (49-70%) were much greater than those seen in parental or scrambled-shRNA transduced cells. We next employed a novel human immortalized erythroid line (HUDEP-2). This line possesses an advantage over lines currently used for globin switching studies because it expresses predominantly adult hemoglobin (HbA: α2β2), with very low background HbF expression. Using CRISPR/cas9 gene modification, we knocked out ZBTB7A in HUDEP-2 cells and performed RNA-Seq analysis. As expected, γ-globin (HBG1 and HBG2) transcripts, but not those of embryonic ε-globin (HBE1), were markedly induced in ZBTB7A KO (ZBTB7AΔ/Δ) HUDEP-2 cells. ZBTB7AΔ/Δ cells exhibited HbF levels greater than 60%, while that of parental cells was less than 3%. Notably, the HbF reactivation occurred without changes in levels of transcripts encoding known HbF repressors, including BCL11A, the principal known switching factor.

We next performed chromatin-immunoprecipitation and sequencing (ChIP-Seq) with an anti-LRF antibody using HSPC-derived proerythroblasts and HUDEP-2 cells. The most enriched motif identified in either was concordant with that previously identified in vitro using CAST analysis (Maeda et. al. Nature 2005), confirming antibody specificity. Supporting a direct role of LRF at the β-globin cluster, we observed several significant enrichment of LRF-ChIP binding signals at adult (HBB), fetal (HBG1) globin loci and the upstream hypersensitivity (HS) sites within the locus control region (LCR). ATAC-Seq (for assay for transposase-accessible chromatin with high-throughput sequencing) analysis revealed strong chromatin accessibility at the γ-globin locus in ZBTB7AΔ/Δcells. Strikingly, differential enrichment of ATAC-signals in ZBTB7AΔ/Δ cells was evident only at the γ-locus. Thus, while LRF binds to the HBB locus and HS sites as well as to the HBG1 locus, LRF depletion specifically opens chromatin at the γ-globin locus.

Finally, to determine whether LRF and BCL11A suppress γ-globin expression via distinct mechanisms, we established LRF/BCL11A double knockout HUDEP-2 cells. Strikingly, HUDEP-2 lines lacking both LRF and BCL11A exhibited almost a complete switch in expression from adult- to fetal-type globin, suggesting that these two factors cumulatively represent the near entirety of γ-globin repressive activity in adult erythroid cells. Our findings reveal a novel molecular mechanism regulating γ-globin silencing and may open a new window for therapeutic targeting in the treatment of hemoglobinopathies.

Contact Information

Send related correspondence and questions regarding abstract submission policies or notifications to [email protected].

Any technical questions regarding navigation of the submission site itself should be directed to [email protected].

ASH Annual Meeting Registration and Housing

  • Please note that submitting an abstract does not register you for the ASH annual meeting.
  • To register, you must complete and return an Attendee Registration Form, or register online through the ASH website.
  • For ASH members, Early-Bird Registration will be available July 17, 2024. During this time, ASH members can access the online meeting registration and hotel reservation program before it is open to the general public.
  • Please note that Early-Bird Registration is available online only, and you must register for the annual meeting before making your hotel reservations.
  • The Preliminary Program, which includes registration, hotel reservation, and program information, will be available online in July 2024.
  • Non-members will be able to find all relevant annual meeting information on the ASH website and can access the online registration and hotel reservation program beginning August 7, 2024.
  • To register as a non-member in training and receive the discounted advance registration rate, you must register and submit your trainee verification via the online registration site by December 8, 2024. Trainee verification will not be accepted at on-site registration in San Diego and the discounted rate will not apply.